Sartorius stock gets a higher Goldman Sachs price target again

Published on 10/05/2026 at 23:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock traded at EUR 250.90 on October 5, 2026, as Goldman Sachs lifted its target to EUR 244. H1 sales rose 7.7 percent and EBITDA reached EUR 548 million.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 250.90 on Xetra on October 5, 2026, up 0.16 percent. The latest analyst signal came from FinanzNachrichten, which reported on September 30, 2026, that Goldman Sachs raised its price target from EUR 228 to EUR 244 while retaining a Neutral rating.

Goldman target rises to EUR 244

Goldman Sachs analyst James Quigley expects Sartorius to post third-quarter operating earnings slightly above consensus, citing a continuing recovery in bioprocessing, according to FinanzNachrichten.

The higher target does not amount to a bullish rating change. Goldman Sachs kept its Neutral view and preferred Sartorius Stedim Biotech, the listed subsidiary, over Sartorius AG preference shares.

H1 growth supports the recovery case

For the first half of 2026, Sartorius reported sales growth of 7.7 percent in constant currencies, underlying EBITDA of EUR 548 million and an underlying EBITDA margin of 30.3 percent, according to Edgechat on September 19, 2026.

The company investor-relations page states that fiscal 2026 guidance calls for constant-currency sales growth of 5 to 9 percent and an underlying EBITDA margin slightly above 30 percent, with Bioprocess Solutions expected to grow 6 to 10 percent in constant currencies, according to Sartorius.

Consensus target remains above the price

MarketScreener listed an Outperform consensus from 20 analysts on September 18, 2026, with an average target of EUR 271.74. That average target was 8.30 percent above the EUR 250.90 Xetra price, keeping the market's recovery expectations ahead of the latest quote.

The next scheduled reporting date is October 21, 2026, when Sartorius is listed to release third-quarter results, according to MarketScreener.

Sartorius stock trades at EUR 250.90

Sartorius stock was trading at EUR 250.90 on Xetra on October 5, 2026, with a daily gain of 0.16 percent. The upcoming third-quarter report will test whether the 7.7 percent first-half sales growth can continue into the second half.